Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.93 - $88.28
Previous CloseN/A
Volume821.68K
Average Volume (3M)3.60M
Market Cap
$44.87B
Enterprise Value$42.34B
Total Cash (Recent Filing)$3.90B
Total Debt (Recent Filing)$699.40M
Price to Earnings (P/E)51.2
Beta0.89
Next Earnings
Jul 24, 2025EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding586,600,000
10 Day Avg. Volume3,848,984
30 Day Avg. Volume3,598,718
Financial Highlights & Ratios
PEG Ratio24.88
Price to Book (P/B)4.47
Price to Sales (P/S)0.00
P/FCF Ratio154.15
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue1.83
Enterprise Value/Gross Profit9.65
Enterprise Value/Ebitda5.93
Forecast
1Y Price Target
$83.87Price Target Upside9.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageEdwards is expected to benefit from Boston Scientific’s retreat from the EU TAVR market, potentially gaining $65M-$100M annually.
Market ExpansionThe company is on a path to resume 10%+ sustainable top-line growth driven by market expansion in TAVR and scaling of TMTT.
Regulatory ApprovalsFDA approval of the SAPIEN 3 platform in asymptomatic patients is expected to unlock a large commercial opportunity for Edwards Lifesciences.
Bears Say
Capacity ConstraintsHospital capacity constraints driven by emerging structural heart therapies have negatively impacted US TAVR volumes in recent quarters.
Growth LimitationsCurrent estimates for US growth are realistic, but significant upside is unlikely due to EVOQUE’s workflow issues and PASCAL’s limited label.
Market Share DeclineSurvey results indicate that Edwards Lifesciences' share in respondents' centers is expected to decline by 1% quarter over quarter in 2Q.
Ownership Overview
0.23% Insiders
22.22% Mutual Funds
1.07% Other Institutional Investors
51.65% Public Companies and
Individual Investors
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $58.93 and its highest was $88.28 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $44.87B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 24, 2025 which is tomorrow.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 23, 2025. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.596 by $0.044.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.62.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 586,600,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.64 in its last earnings report, beating expectations of $0.596. Following the earnings report the stock price went up 6.628%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$83.87 (9.55% Upside)
$83.87 (9.55% Upside)
Blogger Sentiment
Bullish
EW Sentiment 87%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 848.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $155.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.86%
12-Months-Change
Fundamentals
Return on Equity
16.73%
Trailing 12-Months
Asset Growth
33.75%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation (EW) is a global leader in the medical device industry, specializing in heart valve technologies and critical care monitoring. The company is renowned for its development, manufacturing, and marketing of innovative products that address structural heart disease and enhance the quality of life for patients. Edwards Lifesciences operates primarily in the sectors of transcatheter heart valves, surgical heart valves, and critical care technologies, providing solutions that are used in both hospital and outpatient settings.
EW Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and strategic advancements, such as significant revenue growth and successful product approvals. However, challenges in the Japan market and anticipated financial impacts from tariffs and acquisitions present potential hurdles.Read More>EW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
EW Stock 12 Month Forecast
Average Price Target
$83.87
▲(9.55%Upside)